The product (2R,3R,4S,5R,6R)-2-bromo-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate), supplied under material code BTHP-PG-01 as a Pharma Grade API, is a single-stereoisomer protected glycosyl bromide with molecular formula C₂₆H₄₇BrO₉ and molecular weight 583.55 g/mol. The material is controlled as a white to off-white crystalline powder and is designated for formulation screening in tablet, capsule, granule, and injectable presentations. No harmonized Ph. Eur., USP–NF, or JP monograph exists for this exact protected halide; release therefore follows an internal specification aligned with ICH Q3A, ICH Q3C, and ICH Q3D. The pivaloyl moieties at C-3, C-4, C-5, and the pivaloyloxymethyl substituent at C-6 provide steric shielding around the bromide-bearing carbon adjacent to the ring oxygen, moderating hydrolysis during solid-state processing while retaining electrophilic reactivity for subsequent glycosylation or substitution. Oral and injectable grades differ principally in bioburden, bacterial endotoxin, sterility, and subvisible particulate controls.

Because the C–Br bond is activated toward nucleophilic displacement, aqueous and alkaline conditions must be excluded during handling. The pivaloyl ester groups are relatively stable at neutral pH but undergo saponification in strong base, releasing pivalate and the unprotected polyol. In formulation laboratories, the material is not combined with primary or secondary amines, alkoxides, carbonate bases, or aqueous buffers above pH 7.0. Handling at relative humidity above 60% or exposure to open air for more than 24 h may raise free water above the ≤0.5% w/w Karl Fischer limit and initiate agglomeration. Bulk containers are opened only under nitrogen or argon in a dry glovebox or isolator.

Solid-state characterisation is performed by X-ray powder diffraction using Cu Kα radiation at 40 kV/40 mA; the powder pattern shows distinct crystalline reflections in the 5–35° 2θ range, but no published reference pattern is available for this exact structure. Particle size distribution is measured by laser diffraction according to ISO 13320:2020 or USP <429>. For oral tablet and capsule grades, the D90 is controlled between 75 µm and 150 µm; for injectable grades, jet milling under nitrogen is used to achieve D90 ≤10 µm. Micronization introduces amorphous surface domains, and the micronised powder is re-analysed by XRPD and Karl Fischer after 24 h equilibration at ≤30% RH. Differential scanning calorimetry at 10 K/min under nitrogen is used to detect low-melting impurities; however, thermal events may overlap with degradation, so interpretation is combined with thermogravimetric analysis and HPLC.

What release and stability-indicating controls define this protected glycosyl bromide as pharma-grade?

The release protocol combines identity, purity, and residual solvent measurements with route-specific microbial and particulate controls. The following table summarises the internal acceptance criteria for the oral-grade powder; the injectable grade applies the same chemical and enantiomeric purity limits but adds endotoxin and subvisible particle requirements.

The HPLC-ELSD method employs a C18 stationary phase and an acetonitrile/0.1% trifluoroacetic acid gradient; ELSD is used because the pivaloyl ester has weak UV absorption. Forced degradation studies per ICH Q1A(R2) and ICH Q1B reveal that the main degradation pathways are hydrolysis of the bromide and de-esterification of the pivaloyl groups; the primary solid-state degradation products are the corresponding 2-hydroxy tetrahydropyran derivative and free pivalic acid. Published data for this specific configuration is limited, so the internal specification applies a total degradation product limit of ≤1.0% at release and requests lot-specific stability data for formulation batches.

For tablet and capsule manufacturing, the crystalline powder is first delumped through a 0.5 mm stainless-steel screen and blended in a bin blender at 10–25 rpm for 10–15 min. The crystal habit is plate-like, and flow is typically poor; direct compression without flow additives is not recommended. Dry granulation by roller compaction is preferred over aqueous wet granulation because of the hydrolytic instability of the bromide. When roller compaction is used, ribbon density is maintained between 1.1 g/cm³ and 1.3 g/cm³, and the milled granule fraction between 0.150 mm and 0.710 mm is selected for compression. Tablet hardness values in development batches have been controlled in the 6–10 kp range, but these results are formulation-dependent and published data for this specific configuration is limited; each formulation must be verified by content uniformity and dissolution testing under USP <905> and USP <711> or Ph. Eur. 2.9.40 and 2.9.3.

Capsule blending uses geometric dilution for low-dose strengths. The compound is compatible with lactose monohydrate, microcrystalline cellulose, crospovidone, and magnesium stearate in short blending cycles; alkaline lubricants such as sodium stearyl fumarate are not used without confirming pH control because pivalate hydrolysis is base-catalysed. Twin-screw extrusion above 45°C is not recommended because thermal elimination of pivalate esters may release isobutylene and pivalic acid. If a granule formulation is required, non-aqueous granulation with isopropanol and vacuum drying at 35–40°C has been used; residual solvent is confirmed by headspace GC before compression.

When Pivaloylation Replaces Acetyl, Benzoyl, or Methoxyacetyl Protection in Oral and Injectable APIs

The pivaloyl protecting group differentiates this API from acetyl-, benzoyl-, and methoxyacetyl-protected analogues. Acetyl esters are less sterically hindered and hydrolyse more rapidly in aqueous media; benzoyl esters introduce aromatic UV chromophores that simplify detection but tend to reduce crystallinity through π-stacking; methoxyacetyl esters provide greater polarity but are generally less stable under acidic conditions. Pivaloyl esters provide greater steric bulk, which reduces hydrolytic deprotection and improves crystallinity. The trade-off is increased lipophilicity and reduced aqueous solubility; injectable formulations therefore require a non-aqueous or surfactant-containing vehicle rather than simple phosphate-buffered saline at pH 7.4. Measured values for the partition coefficient of this exact compound are not available; fragment-based estimates indicate log P exceeds 5, but the value should be confirmed experimentally before final formulation design.

Compared with unprotected or acetyl-protected glycosyl halides, the pivaloylated material is less hygroscopic and shows a lower tendency to undergo spontaneous elimination during storage at -20°C ± 5°C. However, the bromide remains reactive enough to require exclusion of thiols, azides, cyanide, and other strong nucleophiles from formulation components. The product is not interchangeable with acetyl-protected starting materials in synthetic routes without re-qualification of reaction stoichiometry, because the steric demand of the pivaloyl group alters glycosylation rates and stereochemical outcomes.

For injectable presentations, the API is handled in an ISO 7 cleanroom under nitrogen overlay. Powder is dissolved in dimethyl sulfoxide or N-methyl-2-pyrrolidone and sterilised by membrane filtration through a 0.22 µm PVDF filter; terminal steam sterilisation is unsuitable because the C–Br bond is hydrolytically unstable at elevated temperature. Lyophilised formulations are prepared from tert-butanol/water mixtures with primary drying shelf temperature below -20°C to prevent melting and degradation. Residual water in the freeze-dried cake is controlled to ≤1.0% w/w by Karl Fischer titration. Subvisible particulate matter is controlled under USP <788>, and bacterial endotoxin is determined by Ph. Eur. 2.6.14/USP <85> with limits derived from the intended maximum bolus dose.

Thermal Degradation and Residual Solvent Behaviour of the Protected Bromide

Thermal stress is a critical processing boundary. Differential scanning calorimetry data for the exact compound are not publicly available; therefore, the material is handled with the conservative limit of 40°C for extended operations and 60°C for not more than 10 min. Above 60°C, pivalate esters can undergo thermal elimination, generating isobutylene and pivalic acid. The bromide itself can undergo debromination in the presence of iodide, phosphines, or tertiary amines; such reagents must not be present in formulation matrices. Residual solvent removal after granulation is carried out in a vacuum tray dryer at 35–40°C and 5–10 kPa; the bed depth is maintained below 2 cm to avoid moisture entrapment. Lot release includes headspace GC for isopropanol, tert-butanol, and methylene chloride according to ICH Q3C Option 1 limits.

Storage stability is assigned a 12-month re-test date when the material is held at -20°C ± 5°C in sealed amber borosilicate vials under argon. Above 2–8°C, hydrolysis of the bromide accelerates; therefore, ambient storage is limited to 72 h for weighed portions in controlled low-humidity isolators. Repeated freeze-thaw cycles of open containers are not recommended because condensed moisture increases water content and promotes de-esterification.

Operational boundaries are defined by the reactivity of the bromide and the base sensitivity of the pivalate esters. The API is incompatible with primary and secondary amines, alkoxides, strong aqueous bases, and metal hydrides. It is not milled in air at high energy for extended periods because electrostatic charging and local hot spots may generate pivalic acid. For oral solid dosage forms, the material is best processed by dry granulation or roller compaction at controlled humidity; for injectable forms, non-aqueous or low-water vehicles are required. Published data for this specific configuration is limited in the public domain; lot-specific certificates of analysis and route-specific qualification batches are required before commercial manufacturing.